ProCE Banner Activity

TROPiCS-02 Subgroup Analysis by Age: Sacituzumab Govitecan vs Treatment of Physician’s Choice in HR+/HER2- MBC

Conference Coverage

In this post hoc analysis of the phase III TROPiCS-02 trial, greater benefit and a manageable safety profile with sacituzumab govitecan vs physician’s choice of treatment was observed across age subgroups in patients with pretreated HR+/HER2- locally advanced/metastatic breast cancer.

Released: December 09, 2023


Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme LLC, and Seagen Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Merck Sharp & Dohme, LLC

Seagen Inc.